Intelligent Medicine Acqu... (IQMDW)
Intelligent Medicine Acquisition Statistics
Share Statistics
Intelligent Medicine Acquisition has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 36.67% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 4.66 and the forward PE ratio is null. Intelligent Medicine Acquisition's PEG ratio is 0.
| PE Ratio | 4.66 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.26 |
| P/FCF Ratio | -61.37 |
| PEG Ratio | 0 |
Enterprise Valuation
Intelligent Medicine Acquisition has an Enterprise Value (EV) of 53.15M.
| EV / Sales | 0 |
| EV / EBITDA | -3.66 |
| EV / EBIT | -61.31 |
| EV / FCF | -61.31 |
Financial Position
The company has a current ratio of 0.17, with a Debt / Equity ratio of 0.
| Current Ratio | 0.17 |
| Quick Ratio | 0.17 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 5.64% and Return on Invested Capital is -6.95%.
| Return on Equity | 5.64% |
| Return on Assets | 5.33% |
| Return on Invested Capital | -6.95% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 562.57K |
| Effective Tax Rate | 4.7% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so Intelligent Medicine Acquisition's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 43.7 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.77M |
| Net Income | 11.41M |
| EBITDA | -14.54M |
| EBIT | -14.54M |
| Earnings Per Share (EPS) | 2.2 |
Balance Sheet
The company has 50.15K in cash and 0 in debt, giving a net cash position of 50.15K.
| Cash & Cash Equivalents | 50.15K |
| Total Debt | 0 |
| Net Cash | 50.15K |
| Retained Earnings | -10.86M |
| Total Assets | 214.03M |
| Working Capital | -891.12K |
Cash Flow
In the last 12 months, operating cash flow was -866.9K and capital expenditures 0, giving a free cash flow of -866.9K.
| Operating Cash Flow | -866.9K |
| Capital Expenditures | 0 |
| Free Cash Flow | -866.9K |
| FCF Per Share | -0.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IQMDW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 21.45% |
| FCF Yield | -1.63% |
Analyst Forecast
Currently there are no analyst rating for IQMDW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 67320.23 |
| Piotroski F-Score | 2 |